ArticleCureus2025
Biocompatibility Analysis of a Herbal Amalgamation Containing Nochi, Vilvam, and Adhimadhuram Ethanolic Extracts on Vero Cell Line.
Article in Cureus, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Objective This study aimed to examine the biocompatibility and potential synergistic therapeutic effects of a blend of ethanolic extracts derived from the medicinal herbs Vilvam, Nochi, and Adhimadhuram on the Vero cell line. Materials and methods The Vero cell line was obtained from the National Centre for Cell Sciences (NCCS), Pune. A herbal formulation was prepared by blending Nochi, Vilvam, and Adhimadhuram ethanolic extracts. The Vero cell line was then evaluated for the effects of the herbal amalgamation at concentrations of 1000 µg, 500 µg, 250 µg, 125 µg, 62.5 µg, 31.2 µg, 15.6 µg, and 7.8 µg with assessments conducted at 24-h and 48-h time points. Untreated cells served as the control. Results The herbal elixir exhibited heightened cytotoxicity on the Vero cells, leading to a corresponding decline in the viable cell percentage as the concentration of the formulation was increased. To evaluate the biocompatibility of the herbal consortium on the Vero cell line, a 3-(4, 5-dimethylthiazol-2-yl)-2, 5-diphenyltetrazolium bromide (MTT) assay was carried out over a 24-48-h period of incubation with seven different concentrations as follows: 500 µg, 250 µg, 125 µg, 62.5 µg, 31.2 µg, 15.6 µg, and 7.8 µg. A dose-dependent cell viability was observed. Every experiment was conducted three times. Conclusion The herbal formulation showcases impressive biocompatibility. The promising initial results from Vero cell testing represent the first step in a potentially lengthy journey toward clinical application. Vero cell testing demonstrated the herbal blend's exceptional capacity to support cell viability with negligible toxicity, strongly indicating its suitability for future biomedical applications. However, realizing the full potential of this promising herbal consortium will necessitate extensive further research, including rigorous animal studies and clinical trials to meticulously evaluate its safety and efficacy. A deeper investigation into the underlying biocompatibility mechanisms and therapeutic properties will be pivotal to unlocking the transformative possibilities of this innovative herbal blend. Given the burgeoning interest in natural and herbal remedies, this formulation holds tremendous promise; however, its full potential can only be realized through rigorous, systematic scientific evaluation.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.